Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Iowa, University of Iowa Holden Comprehensive Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Chicago, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Stanford Medicine, Stanford University, Harvard University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3029840434